4 results about "Interleukin-1beta" patented technology

The present disclosure relates to methods of treating cancer comprising administering to a subject an IRAK4 modifying compound wherein the subject has irregular expression of a gene associated with NF-KB.

The present disclosure relates to methods of treating cancer comprising administering to a subject an IRAK4 modifying compound wherein the subject has irregular expression of a gene associated with NF-KB.

The invention belongs to the technical field of pharmacy, and discloses application of physcion in preparation of a medicine for treating fungal keratitis. The invention proposes that the physcion can inhibit the growth of corneal fungi for the first time, and has a treatment effect on fungal keratitis under in-vivo and in-vitro conditions. In an in-vivo experiment, a fungal keratitis model is established by adopting a C57BL / 6 mouse, and the influence of the physcion on the corneal clinical score of the model mouse, the recruitment of macrophages and neutrophils and the expression of NF-kB and interleukin 1beta is researched. In-vitro experiments prove that emodin monomethyl ether with different concentrations has an inhibiting effect on growth of aspergillus fumigatus, and meanwhile, an aspergillus fumigatus stimulated mouse macrophage model verifies the influence of emodin monomethyl ether on an NF-kB / IL-1beta signal channel.

The invention discloses application of dehydrocostus lactone and a medicine for treating steatohepatitis, relates to the technical field of biological medicines, and solves the problems that in the prior art, the application scene of the dehydrocostus lactone is limited, and the application of the dehydrocostus lactone in a complex pathological environment of metabolic dysfunction related steatohepatitis has a technical blank. Dehydrocostus lactone can reduce lipid accumulation, inflammation and fibrosis in liver cells; the weight, liver weight, serum triglyceride content, serum total cholesterol content and insulin resistance level of animals with steatohepatitis are reduced; the content of serum glutamic oxalacetic transaminase, glutamic-pyruvic transaminase, tumor necrosis factor alpha, interleukin 1beta, malondialdehyde and bivalent ferrous ions is reduced, and the content of serum glutathione is increased; the compound can regulate and control lipid metabolism and mitochondrial energy metabolism pathways, reprograms fatty degeneration liver cell energy metabolism phenotypes, and is applied to preparation of drugs for treating steatohepatitis, ferroptosis inhibitors and glutamic oxalacetic transaminase and / or glutamic-pyruvic transaminase inhibitors.